Prognostic significance of immunohistochemical classification of diffuse large B-cell lymphoma

被引:17
作者
Alacacioglu, Inci [1 ]
Ozcan, Mehmet Ali [1 ]
Ozkal, Sermin [2 ]
Piskin, Ozden [1 ]
Turgut, Nurhilal [1 ]
Demirkan, Fatih [1 ]
Ozsan, Guner Hayri [1 ]
Kargi, Aydanur [2 ]
Undar, Bulent [1 ]
机构
[1] Dokuz Eylul Univ, Fac Med, Div Hematol, TR-35340 Izmir, Turkey
[2] Dokuz Eylul Univ, Fac Med, Dept Pathol, TR-35340 Izmir, Turkey
关键词
Lymphoma; prognosis; CD10; bcl-6; mum-1; bcl-2; GERMINAL-CENTER; PROTEIN EXPRESSION; TISSUE MICROARRAY; BCL-6; PROTEIN; R-CHOP; CD10; SUBSET; IMPACT; IDENTIFICATION; CHEMOTHERAPY;
D O I
10.1179/102453309X385205
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Aim: To evaluate the clinical significance of immunoperoxidase staining for CD10, bcl-6, mum-1 and bcl-2 to subdivide DLBCL into prognostic subgroups, we analysed 50 DLBCL cases using immunohistochemical methods. Methods and results: Fifty DLBCL patients were evaluated retrospectively. The expression of CD10 was associated with better OS (p=0.04) whereas expression of mum-1 was associated with worse OS (p=0.009). There were no significance of OS in case of expression of bcl-6 (p=0.05) and bcl-2 (p=0.3). They were subclassified using CD10, mum-1, bcl-6 as germinal center B-cell like (GCB) lymphoma (30%) and non-GCB lymphoma (70%). The OS and EFS (event free survival) were longer in GCB group (p=0.002) and 5-year OS for GCB group was 92% compared with only 44% for the non-GCB group (p=0.02). The OS of the GCB group also was longer compared to that of the non-GCB group in low IPI subgroup (p=0.01). Conclusion: The existance of survival differences between GCB a non-GCB group also in the patients with low IPI score, showed the importance of prognostic classification in the risk-adaptive treatment approaches. The classification as GCB and non-GCB based immunostains may enable to define more accurate prognostic groups in DLBCL.
引用
收藏
页码:84 / 89
页数:6
相关论文
共 31 条
[11]   A monoclonal antibody (MUM1p) detects expression of the MUM 1/IRF4 protein in a subset of germinal center B cells, plasma cells, and activated T cells [J].
Falini, B ;
Fizzotti, M ;
Pucciarini, A ;
Bigerna, B ;
Marafioti, T ;
Gambacorta, M ;
Pacini, R ;
Alunni, C ;
Natali-Tanci, L ;
Ugolini, B ;
Sebastiani, C ;
Cattoretti, G ;
Pileri, S ;
Dalla-Favera, R ;
Stein, H .
BLOOD, 2000, 95 (06) :2084-2092
[12]   Proteins encoded by genes involved in chromosomal alterations in lymphoma and leukemia: clinical value of their detection by immunocytochemistry [J].
Falini, B ;
Mason, DY .
BLOOD, 2002, 99 (02) :409-426
[13]   Emerging prognastic factors in diffuse large B cell lymphoma [J].
Gascoyne, RD .
CURRENT OPINION IN ONCOLOGY, 2004, 16 (05) :436-441
[14]  
Haarer CF, 2006, ARCH PATHOL LAB MED, V130, P1819
[15]   Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray [J].
Hans, CP ;
Weisenburger, DD ;
Greiner, TC ;
Gascoyne, RD ;
Delabie, J ;
Ott, G ;
Müller-Hermelink, HK ;
Campo, E ;
Braziel, RM ;
Jaffe, ES ;
Pan, ZG ;
Farinha, P ;
Smith, LM ;
Falini, B ;
Banham, AH ;
Rosenwald, A ;
Staudt, LM ;
Connors, JM ;
Armitage, JO ;
Chan, WC .
BLOOD, 2004, 103 (01) :275-282
[16]   BCL2 translocation defines a unique tumor subset within the germinal center B-cell-like diffuse large B-cell lymphoma [J].
Iqbal, J ;
Sanger, WG ;
Horsman, DE ;
Rosenwald, A ;
Pickering, DL ;
Dave, B ;
Dave, S ;
Xiao, L ;
Cao, KJ ;
Zhu, QM ;
Sherman, S ;
Hans, CP ;
Weisenburger, DD ;
Greiner, TC ;
Gascoyne, RD ;
Ott, G ;
Müller-Hermelink, HK ;
Delabie, J ;
Braziel, RM ;
Jaffe, ES ;
Campo, E ;
Lynch, JC ;
Connors, JM ;
Vose, JM ;
Armitage, JO ;
Grogan, TM ;
Staudt, LM ;
Chan, WC .
AMERICAN JOURNAL OF PATHOLOGY, 2004, 165 (01) :159-166
[17]   Tissue microarray is inappropriate for analysis of BCL6 expression in diffuse large B-cell lymphorna [J].
Linderoth, Johan ;
Ehinger, Mats ;
Akerman, Mans ;
Cavallin-Stahl, Eva ;
Enblad, Gunilla ;
Erlanson, Martin ;
Jerkeman, Mats .
EUROPEAN JOURNAL OF HAEMATOLOGY, 2007, 79 (02) :146-149
[18]   Prognostic significance of Ki-67 nuclear proliferative antigen, bcl-2 protein, and p53 expression in follicular and diffuse large B-cell lymphoma [J].
Llanos, M ;
Alvarez-Argüelles, H ;
Alemán, R ;
Oramas, J ;
Díaz-Flores, L ;
Batista, N .
MEDICAL ONCOLOGY, 2001, 18 (01) :15-22
[19]   Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL) [J].
Mounier, N ;
Briere, J ;
Gisselbrecht, C ;
Emile, JF ;
Lederlin, P ;
Sebban, C ;
Berger, F ;
Bosly, A ;
Morel, P ;
Tilly, H ;
Bouabdallah, R ;
Reyes, F ;
Gaulard, P ;
Coiffier, B .
BLOOD, 2003, 101 (11) :4279-4284
[20]   Immunohistochemical profiling based on Bcl-2, CD10 and MUMI expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma [J].
Muris, JJF ;
Meijer, CJLM ;
Vos, W ;
van Krieken, JHJM ;
Jiwa, NM ;
Ossenkoppele, GJ ;
Oudejans, JJ .
JOURNAL OF PATHOLOGY, 2006, 208 (05) :714-723